{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:03:55Z","timestamp":1758272635543,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bulcan.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T17:12:55Z","timestamp":1678209175000},"page":"570-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of immunotherapy according to the age threshold of 80 years"],"prefix":"10.1016","volume":"110","author":[{"given":"Soraya","family":"Mebarki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pamoukdjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Pierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne","family":"Poisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Widad\u00a0Lahlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Canoui-Poitrine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Paillaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2023.02.010_bib0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.010_bib0135","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1002\/jcp.29371","article-title":"The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"235","author":"Wang","year":"2020","journal-title":"J Cell Physiol"},{"issue":"19","key":"10.1016\/j.bulcan.2023.02.010_bib0140","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.3390\/cancers13195026","article-title":"Immune therapies for myelodysplastic syndromes and acute myeloid leukemia","volume":"13","author":"Kapoor","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.010_bib0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.31664","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.010_bib0150","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1634\/theoncologist.2019-0166","article-title":"Inclusion of older patients with cancer in clinical trials: the SAGE Prospective Multicenter Cohort Survey","volume":"24","author":"Canou\u00ef-Poitrine","year":"2019","journal-title":"The Oncologist"},{"key":"10.1016\/j.bulcan.2023.02.010_bib0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.010_bib0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2019.05.013","article-title":"Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis","volume":"11","author":"Kasherman","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.bulcan.2023.02.010_bib0165","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.010_bib0170","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-021-00899-7","article-title":"Safety and effectiveness of immune checkpoint inhibitors in older patients with cancer: a systematic review of 48 real-world studies","volume":"38","author":"Luciani","year":"2021","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.010_bib0175","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a Multicenter International Cohort Study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.010_bib0180","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.010_bib0185","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.010_bib0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"9","key":"10.1016\/j.bulcan.2023.02.010_bib0195","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","article-title":"Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.010_bib0200","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.010_bib0205","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/14740338.2021.1939672","article-title":"The effect of patient sex on the efficacy and safety of anticancer immunotherapy","volume":"20","author":"Pala","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.010_bib0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.010_bib0215","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.010_bib0220","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.7150\/jca.40196","article-title":"Sex differences and adverse effects between chemotherapy and immunotherapy for non-small cell lung cancer","volume":"11","author":"Tsiouda","year":"2020","journal-title":"J Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.010_bib0225","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex Differences in Tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.010_bib0230","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.4049\/jimmunol.0803205","article-title":"Membrane estrogen receptor regulates EAE through upregulation of programmed death 1","volume":"182","author":"Wang","year":"2009","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.010_bib0235","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00262-021-02882-y","article-title":"Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma","volume":"70","author":"Tulchiner","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.010_bib0240","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.010_bib0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jgo.2019.05.021","article-title":"Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors","volume":"11","author":"Welaya","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.bulcan.2023.02.010_bib0250","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0959-8049(17)30456-2","article-title":"DIALOG task force for definition of a geriatric minimum data set for clinical oncology research","volume":"72","author":"Paillaud","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:33Z","timestamp":1757792253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0007455123000978"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of immunotherapy according to the age threshold of 80 years","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}